| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/CJI.0000000000000003 |
| P698 | PubMed publication ID | 24145360 |
| P50 | author | Igor Puzanov | Q66829274 |
| Janice P Dutcher | Q90323603 | ||
| P2093 | author name string | Jeffrey A Sosman | |
| Michael B Atkins | |||
| David F McDermott | |||
| Joseph I Clark | |||
| Walter J Urba | |||
| Todd S Crocenzi | |||
| Meredith M Regan | |||
| Musie Ghebremichael | |||
| Ulka N Vaishampayan | |||
| Brendan D Curti | |||
| Marc S Ernstoff | |||
| Kim A Margolin | |||
| Nancy A Crosby | |||
| Uday B Dandamudi | |||
| P433 | issue | 9 | |
| P921 | main subject | interleukins | Q194908 |
| bevacizumab | Q413299 | ||
| renal cell carcinoma | Q1164529 | ||
| metastatic renal cell carcinoma | Q19000948 | ||
| P304 | page(s) | 490-495 | |
| P577 | publication date | 2013-11-01 | |
| P1433 | published in | Journal of Immunotherapy | Q15763946 |
| P1476 | title | A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study | |
| P478 | volume | 36 |
| Q38865046 | A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies |
| Q26796316 | Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12 |
| Q38792909 | Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation |
| Q90116668 | Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma |
| Q98286782 | Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials |
| Q33417698 | Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg). |
| Q38913703 | Evolving Immunotherapy Approaches for Renal Cell Carcinoma. |
| Q59400683 | High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 |
| Q26796309 | Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy |
| Q38783324 | Immuno-oncology for renal cell carcinoma treatment: future perspectives for combinations and sequences with molecularly targeted agents |
| Q35802508 | Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review |
| Q38834167 | Immunotherapy of advanced renal cell carcinoma: Current and future therapies |
| Q38819745 | Recent advances in immuno-oncology and its application to urological cancers |
| Q35803551 | SGK3 (CISK) may induce tumor angiogenesis (Hypothesis). |
| Q37281838 | Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy |
| Q38910154 | The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. |
Search more.